On April 11, 2024, T2 Biosystems, Inc., a company incorporated in Delaware and listed on the Nasdaq Capital Market under the trading symbol TTOO, held a special meeting of stockholders. The meeting was conducted to vote on the approval of the CRG Debt to Equity Conversion. Stockholders representing approximately 35.86% of the voting power of the issued and outstanding common stock were present either in person via live webcast or by proxy. The proposal for the CRG Debt to Equity Conversion received overwhelming support with 1,684,394 votes for, 60,832 against, and 23,645 abstentions, leading to its approval. The definitive Proxy Statement provided additional information on the proposals submitted to stockholders.

On April 11, 2024, T2 Biosystems, Inc., a company incorporated in Delaware and listed on the Nasdaq Capital Market under the trading symbol TTOO, held a special meeting of stockholders. The meeting was conducted to vote on the approval of the CRG Debt to Equity Conversion. Stockholders representing approximately 35.86% of the voting power of the issued and outstanding common stock were present either in person via live webcast or by proxy. The proposal for the CRG Debt to Equity Conversion received overwhelming support with 1,684,394 votes for, 60,832 against, and 23,645 abstentions, leading to its approval. The definitive Proxy Statement provided additional information on the proposals submitted to stockholders.